Updates from GAIA/CLL13 trial: impact of complex karyotype on outcomes in CLL скачать в хорошем качестве

Updates from GAIA/CLL13 trial: impact of complex karyotype on outcomes in CLL

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, gives an update from a prospective analysis of the GAIA/CLL13 trial (NCT02950051), which evaluated the impact of complex karyotype in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based (ven-based) time-limited combinations. Prof. Kater describes that this study identified having three or more aberrations as being a poor prognostic marker in the context of chemoimmunotherapy, while having five or more aberrations is a poor prognostic marker for ven-based combination treatment in CLL. In addition, the study found that translocations were an adverse prognostic feature in patients treated with both chemoimmunotherapy and ven-based combinations. Finally, Prof. Kater explains that the number of patients with a complex karyotype and aberrations increased more following chemoimmunotherapy compared to ven-based treatment. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.